CSF Hypo-Inflammation Drives Mortality in HIV-Associated Tuberculous Meningitis
Preprint
Abstract
Background: Excessive CNS inflammation is associated with poor outcomes in tuberculous meningitis (TBM). Anti-inflammatory corticosteroid therapy improves survival in HIV-negative TBM, but not in people with HIV. In people with HIV, TBM is fatal in 40-50% of cases. Therefore, we investigated how mortality is associated with the local immune dynamics in people with HIV-associated TBM. Methods: We measured baseline concentrations of immune signaling mediators in cerebrospinal fluid (CSF) of 149 adults with HIV in Uganda, who presented with definite or probable TBM. Participants received both antimycobacterial and corticosteroid therapy. Results: Non-survivors had more severe TBM disease stage and lower blood CD4 T cells than survivors at baseline. Mortality at 90 days was strongly associated with CSF hypo-inflammation. CSF interferon gamma (IFN-γ) was the cytokine most differentially expressed by survivors (2.2 log 2 -fold change higher, p=.003), and 90-day mortality was lower with increasing concentrations (Tertile-1=50%, Tertile-2=41%, Tertile-3=18%; p=.006). Even among people who successfully mounted a CSF cellular immune response (>5 white cells/μL CSF), those with low CSF IFN-γ had higher risk of death (Hazard Ratio =3.10 (1.44– 6.68). In contrast, people with intermediate CSF interleukin-13 had lower mortality than extreme (Tertile-1=45%, Tertile-2=22%, Tertile-3=40%; p=.017). Of all sub-groups, those with both peripheral CD4 depletion and low CSF IFN-γ had the highest mortality (63%). Conclusions: In adults with HIV-associated TBM receiving dexamethasone, mortality was strongly associated with CSF hypo-inflammation. Although steroids may be appropriate in those with high inflammation, personalized approaches to immunotherapy are likely necessary to improve outcomes.Keywords
This publication has 28 references indexed in Scilit:
- Finding and filling the knowledge gaps in mechanisms of T cell-mediated TB immunity to inform vaccine designNature Reviews Immunology, 2025
- Advancing the chemotherapy of tuberculous meningitis: a consensus viewThe Lancet Infectious Diseases, 2024
- Immune cell characteristics and cytokine responses in adult HIV-negative tuberculous meningitis: an observational cohort studyScientific Reports, 2019
- The pathogenesis of tuberculous meningitisJournal of Leukocyte Biology, 2019
- Meta-Analysis: The Association Between HIV Infection and Extrapulmonary TuberculosisLung, 2012
- Tuberculous meningitis: a uniform case definition for use in clinical researchThe Lancet Infectious Diseases, 2010
- Proinflammatory cytokine levels in the serum and cerebrospinal fluid of tuberculous meningitis patientsNeuroscience Letters, 2008
- Dexamethasone for the Treatment of Tuberculous Meningitis in Adolescents and AdultsNew England Journal of Medicine, 2004
- The damage-response framework of microbial pathogenesisNature Reviews Microbiology, 2003
- Chemokine profiles in the cerebrospinal fluid (CSF) during the course of pyogenic and tuberculous meningitisClinical and Experimental Immunology, 1998